|
||||
 |
||||
Dockets
Management |
||||
|
1995S-0316 Volume 275 Appendix A - Chemical structure of SDG and its metabolic conversion to enterodiol and enterolactone Appendix
B - Selected key papers cited in this NDI notification dossier Appendix C - BeneFlax Flax Lignan extract technical datasheet and certificate of analysis for 3 production lots Appendix D - Analysis of BeneFlax Flax Lignans, flaxseed and flax meal for FDA-NDI submission Appendix E - Determination of compounds present in flax lignans by LC-PDA-MS Appendix F - Averaged numeric values for four process lots used to graph ratios of flax component concentrations at sequential SDG processing steps Appendix G - Outside laboratory pesticides testing reports for 3 production lots (0602081, 0602231 & 0603031) and 2 pilot lots (K0546A & K0548A) of BeneFlax Flax Lignan extract Appendix H - Outside laboratory dioxins/PCB's testing reports for 3 production lots (0602081, 0602231 & 0603031) and 3 pilot lots (K0544B, K0546A & K0548A) of BeneFlax Flax Lignan extract Appendix I - Outside laboratory mycotoxins testing report for 3 production lots of BeneFlax Flax Lignan extract Appendix J - Online search of FDA website on flaxseeds and flaxseed lignans Appendix K - Medline and CAplus literature search on flaxseed lignans safety and toxicity Published Material Appendix L - Summary of literature review on animal and human studies using flaxseeds or flax lignans Published Material Appendix M - Independent report on "The potential estrogenicity of SDG flax lignan extract" Appendix N - Global new products database showing products containing flax or flax lignans and commercial products containing flax ingredients Appendix O - FDAs letters on history of safe use of flaxseeds and flax products Volumes 276-277 Published Material Volume 278 Summary of literature on animal and human studies using flaxseeds or flax lignans References Published Material Page last updated
November 15, 2006
RSC |
